Sceening Limits For Therapeutic Substances

 Australian Racing Board

Screening Limits for Therapeutic Substances

For the purpose of AR.178EA, it is hereby notified that screening limits applicable to the following therapeutic substances, as approved by the Australian Racing Board, are set out as follows:

• acepromazine – 10 nanograms per millilitre (ng/ml) of the 2-(1-hydroxyethyl) promazine sulphoxide metabolite in urine

• betamethasone – 0.20ng/ml in urine

• butorphanol – 1ng/ml in urine

• carprofen – 100ng/ml in urine

• detomidine – 2ng/ml of the 3’-hydroxydetomidine metabolite in urine

• diclofenac – 50ng/ml in urine

• dipyrone – 1000ng/ml of the 4-methylaminoantipyrine metabolite in urine

• eltenac – 50ng/ml in urine

• flunixin – 100ng/ml in urine

• frusemide – 50ng/ml in urine

• hyoscine butylbromide (or n-butylscopolammonium) – 25ng/ml in urine

• ipratropium – 0.25ng/ml in urine

• ketoprofen – 100ng/ml in urine

• lignocaine – 10ng/ml of the 3’-hydroxylignocaine metabolite in urine

• meclofenamic acid – 250ng/ml in urine

• meloxicam – 10ng/ml in urine

• mepivacaine – 10ng/ml of the 3’-hydroxymepivacaine metabolite in urine

• naproxen – 250ng/ml in urine

• phenylbutazone – 100ng/ml in urine

• romifidine – 1ng/ml in urine

• triamcinolone acetonide – 0.5ng/ml in urine

• vedaprofen – 50ng/ml in urine”